Literature DB >> 1325466

Discriminative affinity labelling of opioid receptors by enkephalin and morphiceptin analogues containing 3-nitro-2-pyridinesulphenyl-activated thiol residues.

Y Shimohigashi1, K Takada, H Sakamoto, H Matsumoto, T Yasunaga, M Kondo, M Ohno.   

Abstract

The thiol groups of leucinthiol, cysteamine and cysteine incorporated into opioid peptides enkephalin and morphiceptin were activated by the 3-nitro-2-pyridinesulphenyl (Npys) group to form mixed disulphides highly reactive to a free thiol. Enkephalin analogues containing Npys-leucinthiol or -cysteine at positions 4, 5 and 6 exhibited high affinities for both mu and delta receptors, while morphiceptin analogues containing Npys-cysteine at positions 4 and 5 showed relatively weak affinity only for mu receptors. When these S-activated opioid peptides were incubated with rat brain membrane preparations, it was found, by binding assay using radiolabelled and non-labelled [D-Ala2,MePhe4,Gly-ol5]enkephalin, that they label mu opioid receptors in a dose-dependent manner. The concentrations required to label half of the receptors were 0.2-2 microM for enkephalins and 10-30 microM for morphiceptins. These results suggested that the thiol group labelled by S-activated enkephalins and morphiceptins is present in the ligand binding site of receptor protein, but not in GTPase-binding protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325466     DOI: 10.1016/0021-9673(92)80140-p

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  Solid Phase Synthesis and Application of Labeled Peptide Derivatives: Probes of Receptor-Opioid Peptide Interactions.

Authors:  Jane V Aldrich; Vivek Kumar; Bhaswati Dattachowdhury; Angela M Peck; Xin Wang; Thomas F Murray
Journal:  Int J Pept Res Ther       Date:  2008-12-01       Impact factor: 1.931

2.  Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.

Authors:  Bhaswati Sinha; Zhengyu Cao; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.